Johnson & Johnson shares increased 2.58% recently, supported by strong oncology sales and a solid Q1 earnings beat with $24.06 billion revenue and $2.70 EPS. The company raised its full-year revenue and EPS guidance, driven by growth in drugs like DARZALEX and TREMFYA despite biosimilar competition. Analysts see a 9.37% upside to $252.01 with a buy recommendation, citing a robust oncology pipeline and dividend stability. Risks include biosimilar erosion, litigation costs, and restructuring, but overall confidence remains high for continued growth and potential gains from an upcoming Orthopaedics business separation.
A 66-year-old retiree in Pennsylvania aimed to generate $55,000 annually from a $1.1 million portfolio but lost $2,400 in tax savings because her IRA automatically reinvested dividends shortly after she sold shares at a loss. This triggered the IRS w...
Nanobiotix and Johnson & Johnson presented early Phase 2 trial data for JNJ-1900 (NBTXR3), a novel nanoradioenhancer, in stage 3 inoperable non-small cell lung cancer (NSCLC). The treatment, combined with chemoradiotherapy and durvalumab, showed an o...
The healthcare sector, particularly healthcare equipment, is currently undervalued compared to historical averages. The iShares U.S. Pharmaceuticals ETF (IHE) has notably outperformed the broader healthcare ETF XLV by 27% over the past year, driven l...
A global survey of 817 bladder cancer patients and 802 urologists reveals that standard treatments like bladder removal surgery and BCG therapy significantly harm patients' physical, emotional, and mental health. Over 90% of patients report negative ...
